These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11136390)

  • 1. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract]   [Full Text] [Related]  

  • 2. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors in haemophilia: a primer.
    DiMichele DM
    Haemophilia; 2000 Jul; 6 Suppl 1():38-40. PubMed ID: 10982266
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
    Lollar P
    J Thromb Haemost; 2004 Jul; 2(7):1082-95. PubMed ID: 15219191
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hemophilia, a changed picture].
    Breederveld C; ten Cate JW; Sixma JJ; Veltkamp JJ
    Ned Tijdschr Geneeskd; 1976 Jan; 120(2):69-70. PubMed ID: 1250448
    [No Abstract]   [Full Text] [Related]  

  • 11. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn-Malmö protocol.
    Schlabe S; van Bremen K; Goldmann G; Oldenburg J; Eis-Hübinger AM; Zeitler H; Spengler U
    Haemophilia; 2019 Mar; 25(2):e117-e120. PubMed ID: 30694010
    [No Abstract]   [Full Text] [Related]  

  • 14. Circulating antibodies in factor VIII deficiency hemophilia: report of case.
    Cudzinowski L
    ASDC J Dent Child; 1979; 46(1):54-6. PubMed ID: 283081
    [No Abstract]   [Full Text] [Related]  

  • 15. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members.
    DiMichele DM; Kroner BL
    Vox Sang; 1999; 77 Suppl 1():31-2. PubMed ID: 10529684
    [No Abstract]   [Full Text] [Related]  

  • 17. Animal models of inhibitors.
    Reipert B; Arruda V; Lillicrap D
    Haemophilia; 2010 Jul; 16 Suppl 5():47-53. PubMed ID: 20590856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
    Parry DH; Bloom AL
    J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII inhibitors in hemophilia.
    Mariani G
    Bilt Hematol Transfuz; 1979; 7(1):3-41. PubMed ID: 121880
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.